Science news

<<  return


 It has been a tremendously exciting ESC Congress, particularly with the advent of highly efficacious monoclonal antibodies to PCSK9 and low-density lipoprotein cholesterol (LDL-C) lowering, with the first event data, which are very promising. We live in exciting times.The PCSK9 inhibitors are promising, not only in individuals with high LDL-C levels, with what we call non-familial hypercholesterolemia (FH). These are individuals whose genes for the LDL receptor appear normal. In FH, the patients have at least one defective gene that is involved in the breakdown of cholesterol carried in LDL and they respond equally well. Typically these antibodies achieve approximately a 60% reduction in LDL-C, even in patients with the most severe forms of FH, with LDL-C levels of 400-500 mg/dL, in whom both alleles coding for the LDL receptor gene are affected.